J. Pikiel

发表

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.

B. Mellado, B. Somer, M. Stöckle, 2014, European urology.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

C. Fuchs, J. Tabernero, B. Melichar, 2014, The Lancet.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

F. Esteva, A. Manikhas, J. Stebbing, 2017, The Lancet. Oncology.

microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study

K. Pogoda, A. Krętowski, W. Biernat, 2020, Diagnostics.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

J. Jassem, E. Senkus, J. Szade, 2013, International journal of clinical and experimental pathology.

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

J. Subramanian, Y. Drew, J. Bosch-Barrera, 2022, Clinical lung cancer.

Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.

M. Desilvio, B. Karaszewska, P. Potemski, 2015, Breast.

Anti-NaPi 2 b antibody – drug conjugate lifastuzumab vedotin ( DNIB 0600 A ) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized , open-label , phase II study

A. Oza, M. Birrer, I. Ray-Coquard, 2018 .

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

A. Oza, M. Birrer, I. Ray-Coquard, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

F. Cappuzzo, K. Syrigos, Michael Thomas, 2016, Lung cancer.

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

D. Schadendorf, P. Ascierto, M. Smylie, 2020, Journal for immunotherapy of cancer.

Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.

C. Tournigand, J. Ajani, D. Ferry, 2018 .

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

R. Greil, G. Steger, M. Wojtukiewicz, 2011, Oncology Research and Treatment.

O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Shin-ichiro Takahashi, A. Oaknin, D. Lorusso, 2021, Oral Abstracts.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.

K. Pogoda, E. Senkus, W. Biernat, 2022, Pathology.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Andreas Sashegyi, Michael Thomas, Federico Cappuzzo, 2014, The Lancet.

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

C. Tournigand, J. Ajani, M. Shah, 2022, Cancers.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

M. Desilvio, B. Karaszewska, P. Potemski, 2014, Breast Cancer Research and Treatment.

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).

M. Desilvio, B. Karaszewska, P. Potemski, 2011 .

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

B. Monk, A. Tinker, A. Oza, 2017 .

1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)

J. Subramanian, J. Bosch-Barrera, R. Kristeleit, 2020 .

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

K. Syrigos, Keunchil Park, L. Paz-Ares, 2017, Lung cancer.

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

A. Manikhas, J. Stebbing, A. Eniu, 2021, Breast Cancer Research and Treatment.

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

J. Stebbing, D. Stroyakovskiy, A. Eniu, 2019, Cancer Chemotherapy and Pharmacology.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST).

P. Rutkowski, J. Siedlecki, A. Wozniak, 2017, Folia biologica.

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

K. Syrigos, Keunchil Park, L. Paz-Ares, 2015 .

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2021, Annals of Oncology.

Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).

R. Motzer, T. Powles, T. Choueiri, 2016 .

Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).

B. Mellado, B. Somer, M. Stöckle, 2011 .